{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T19:58:27Z","timestamp":1782417507849,"version":"3.54.5"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008375","name":"Universit\u00e4t Basel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006484","name":"Vifor Pharma Management AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100025010","name":"Dipartimento di Scienze del Farmaco, Universit\u00e0 degli Studi di Padova","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jconrel.2026.114859","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:31:40Z","timestamp":1774283500000},"page":"114859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Charge-driven lipid nanoparticle encapsulation of enzymes for enhanced ERT with reduced immunogenicity"],"prefix":"10.1016","volume":"394","author":[{"given":"Boris","family":"Sevarika","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad\u00e8le","family":"Couvidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Aldawod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita C.","family":"Dinamarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.114859_bb0005","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S1474-4422(04)00938-X","article-title":"Enzyme-replacement therapy for metabolic storage disorders","volume":"3","author":"Brady","year":"2004","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jconrel.2026.114859_bb0010","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1474-4422(24)00518-0","article-title":"Clinical insights in enzyme replacement therapy for metabolic storage disorders: lessons from Pompe disease","volume":"24","author":"van der Beek","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jconrel.2026.114859_bb0015","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2017.05.004","article-title":"Lysosomal enzyme replacement therapies: historical development, clinical outcomes, and future perspectives","volume":"118","author":"Solomon","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114859_bb0020","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJM197411072911901","article-title":"Replacement therapy for inherited enzyme deficiency","volume":"291","author":"Brady","year":"1974","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.114859_bb0025","doi-asserted-by":"crossref","first-page":"291","DOI":"10.21037\/atm.2019.04.15","article-title":"Challenges in treating Pompe disease: an industry perspective","volume":"7","author":"Do","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.114859_bb0030","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clim.2019.01.009","article-title":"HLA- and genotype-based risk assessment model to identify infantile onset Pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA)","volume":"200","author":"De Groot","year":"2019","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jconrel.2026.114859_bb0035","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jconrel.2026.114859_bb0040","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000200746","article-title":"Long-term safety and efficacy of Avalglucosidase alfa in patients with late-onset Pompe disease","volume":"99","author":"Dimachkie","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.jconrel.2026.114859_bb0045","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev.ph.28.030166.002251","article-title":"Functions of lysosomes","volume":"28","author":"de Duve","year":"1966","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.jconrel.2026.114859_bb0050","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/adhm.201500746","article-title":"\u0391-Galactosidase-a loaded-Nanoliposomes with enhanced enzymatic activity and intracellular penetration","volume":"5","author":"Cabrera","year":"2016","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2026.114859_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114464","article-title":"Current treatment options and novel nanotechnology-driven enzyme replacement strategies for lysosomal storage disorders","volume":"188","author":"Del Grosso","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114859_bb0060","doi-asserted-by":"crossref","first-page":"11197","DOI":"10.1039\/D0CP00693A","article-title":"Biomolecule-polymer hybrid compartments: combining the best of both worlds","volume":"22","author":"Meyer","year":"2020","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.jconrel.2026.114859_bb0065","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1021\/acs.molpharmaceut.0c00615","article-title":"Protein delivery by peptide-based stealth liposomes: a biomolecular insight into enzyme replacement therapy","volume":"17","author":"Santi","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.114859_bb0070","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1042\/bj1290123","article-title":"Lysosomal localization of \u03b2-fructofuranosidase-containing liposomes injected into rats. Some implications in the treatment of genetic disorders","volume":"129","author":"Gregoriadis","year":"1972","journal-title":"Biochem. J."},{"key":"10.1016\/j.jconrel.2026.114859_bb0075","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1432-1033.1972.tb19710.x","article-title":"Fate of protein-containing liposomes injected into rats: an approach to the treatment of storage diseases","volume":"24","author":"Gregoriadis","year":"1972","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.jconrel.2026.114859_bb0080","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0014-5793(71)80109-6","article-title":"Enzyme entrapment in liposomes","volume":"14","author":"Gregoriadis","year":"1971","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jconrel.2026.114859_bb0085","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid nanoparticles from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114859_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114859_bb0095","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/laban0511-155","article-title":"Retro-orbital injections in mice","volume":"40","author":"Yardeni","year":"2011","journal-title":"Lab Anim. (NY)"},{"key":"10.1016\/j.jconrel.2026.114859_bb0100","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/mt.2009.195","article-title":"Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine Pompe disease","volume":"18","author":"Sun","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.114859_bb0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1472-6750-2-9","article-title":"Protein encapsulation in liposomes: efficiency depends on interactions between protein and phospholipid bilayer","volume":"2","author":"Colletier","year":"2002","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.jconrel.2026.114859_bb0110","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.chemphyslip.2012.03.006","article-title":"Factors affecting DNA binding and stability of association to cationic liposomes","volume":"165","author":"Even-Chen","year":"2012","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.jconrel.2026.114859_bb0115","series-title":"Major Limitations in the Use of Cationic Liposomes for DNA Delivery","author":"Filion","year":"1998"},{"key":"10.1016\/j.jconrel.2026.114859_bb0120","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1039\/D4PM00128A","article-title":"Tailoring lipid nanoparticle dimensions through manufacturing processes","volume":"1","author":"McMillan","year":"2024","journal-title":"RSC Pharm."},{"key":"10.1016\/j.jconrel.2026.114859_bb0125","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jconrel.2019.04.015","article-title":"Lipid nanoparticles for delivery of messenger RNA to the back of the eye","volume":"303","author":"Patel","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114859_bb0130","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nnano.2007.223","article-title":"Immunological properties of engineered nanomaterials","volume":"2","author":"Dobrovolskaia","year":"2007","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.114859_bb0135","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.2147\/IJN.S36111","article-title":"The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles","volume":"7","author":"Fr\u00f6hlich","year":"2012","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.114859_bb0140","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114859_bb0145","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1021\/ma60077a009","article-title":"Conformations of polymers attached to an Interface","volume":"13","author":"de Gennes","year":"1980","journal-title":"Macromolecules"},{"key":"10.1016\/j.jconrel.2026.114859_bb0150","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/0300-9084(90)90050-Q","article-title":"Acylation of l-asparaginase with total retention of enzymatic activity","volume":"72","author":"Martins","year":"1990","journal-title":"Biochimie"},{"key":"10.1016\/j.jconrel.2026.114859_bb0155","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11095-014-1447-7","article-title":"Superoxide dismutase Enzymosomes: carrier capacity optimization, in vivo behaviour and therapeutic activity","volume":"32","author":"Corvo","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.114859_bb0160","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0005-2736(02)00702-2","article-title":"Design and characterization of enzymosomes with surface-exposed superoxide dismutase","volume":"1609","author":"Gaspar","year":"2003","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.jconrel.2026.114859_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-3659(96)01473-3","article-title":"Liposomal formulations of Cu,Zn-superoxide dismutase: physico-chemical characterization and activity assessment in an inflammation model","volume":"43","author":"Corvo","year":"1997","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114859_bb0170","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nbt.3081","article-title":"Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo","volume":"33","author":"Zuris","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.114859_bb0175","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01263-3","article-title":"Structure of human lysosomal acid \u03b1-glucosidase-a guide for the treatment of Pompe disease","volume":"8","author":"Roig-Zamboni","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114859_bb0180","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1016\/j.bpj.2021.03.012","article-title":"Encapsulation state of messenger RNA inside lipid nanoparticles","volume":"120","author":"Brader","year":"2021","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2026.114859_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202304977","article-title":"Real-time pH-dependent self-assembly of Ionisable lipids from COVID-19 vaccines and in situ nucleic acid complexation","volume":"62","author":"Yu","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2026.114859_bb0190","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jconrel.2024.07.046","article-title":"A perspective on bleb and empty LNP structures","volume":"373","author":"Simonsen","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114859_bb0195","author":"Zhu"},{"key":"10.1016\/j.jconrel.2026.114859_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114708","article-title":"Nanoparticle biodistribution coefficients: a quantitative approach for understanding the tissue distribution of nanoparticles","volume":"194","author":"Kumar","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114859_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107611","article-title":"Hypersensitivity infusion-associated reactions induced by enzyme replacement therapy in a cohort of patients with late-onset Pompe disease: an experience from the French Pompe registry","volume":"139","author":"Lessard","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.jconrel.2026.114859_bb0210","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.jconrel.2026.114859_bb0215","doi-asserted-by":"crossref","first-page":"285","DOI":"10.21037\/atm.2019.05.27","article-title":"Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review","volume":"7","author":"Desai","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.114859_bb0220","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nbt.1484","article-title":"Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment","volume":"26","author":"Wang","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.114859_bb0225","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s40265-021-01621-y","article-title":"Mechanisms of neutralizing anti-drug antibody formation and clinical relevance on therapeutic efficacy of enzyme replacement therapies in Fabry disease","volume":"81","author":"Lenders","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2026.114859_bb0230","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2006.09.003","article-title":"The long-term international safety experience of imiglucerase therapy for Gaucher disease","volume":"90","author":"Starzyk","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.jconrel.2026.114859_bb0235","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human \u03b1-L-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.jconrel.2026.114859_bb0240","article-title":"Characterization of immune response in cross-reactive immunological material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy","volume":"20","author":"Desai","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.jconrel.2026.114859_bb0245","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926002610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926002610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T01:03:20Z","timestamp":1779757400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926002610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":49,"alternative-id":["S0168365926002610"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114859","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Charge-driven lipid nanoparticle encapsulation of enzymes for enhanced ERT with reduced immunogenicity","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114859","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114859"}}